SPATA2L

Across TCGA pan-cancer cohorts, SPATA2L mass-spec protein differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of SPATA2L’s most consistent transcriptional readouts.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where SPATA2L mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types SPATA2L is over-expressed in tumor, although a few such as LSCC show the opposite, repressed pattern.

PDAC and LSCC are the cancer types where SPATA2L tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SPATA2L mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
PDAC	All	All	+0.503	.001	4	view →
LSCC	Male	All	−0.325	<.001	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 2 strongest of 2 lineages.

SPATA2L–PDAC

Open the PDAC breakdown →